| pubmed-article:8491237 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8491237 | lifeskim:mentions | umls-concept:C0002421 | lld:lifeskim |
| pubmed-article:8491237 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8491237 | lifeskim:mentions | umls-concept:C1512045 | lld:lifeskim |
| pubmed-article:8491237 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8491237 | pubmed:dateCreated | 1993-6-11 | lld:pubmed |
| pubmed-article:8491237 | pubmed:abstractText | Ambroxol is known to promote bronchial secretion and is used as an expectorant. Previous studies had suggested that high doses of ambroxol could reduce the plasma uric acid concentration. The present study was undertaken to confirm this finding, to determine its dose-response relationship and to identify the underlying mechanism of action. Using a placebo-controlled, double-blind parallel group design, 48 healthy male volunteers were randomly allocated to receive placebo b.d. and ambroxol 125 mg b.d., 250 mg b.d. or 500 mg b.d. (12 subjects per group). The subjects were hospitalised during a dietary run-in period of 3 days (Days -3 to -1) and a treatment period of 5 days (Days 1 to 5). On Day -1 (baseline) and Days 1 to 5, all urine was collected and blood samples were taken for the analysis of uric acid, creatinine, xanthine and ambroxol. The measurements were repeated four days after treatment had closed. Steady state plasma concentrations of ambroxol (trough levels) were reached after 2 or 3 days and were linearly related to dose. Ambroxol induced a significant, dose-dependent, reduction in plasma uric acid (250 mg b.d. about 20%; and at 500 mg b.d. about 30%). The diurnally fluctuating uric acid clearance was dose dependently increased and there was no notable effect on creatinine clearance. Plasma hypoxanthine levels were not affected by ambroxol. No severe adverse events were reported and no drug induced changes in the clinical laboratory values were observed. It is concluded that ambroxol has an uricosuric action following oral administration of higher doses (250 mg-500 mg b.d.) and it is well tolerated. | lld:pubmed |
| pubmed-article:8491237 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8491237 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8491237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8491237 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8491237 | pubmed:issn | 0031-6970 | lld:pubmed |
| pubmed-article:8491237 | pubmed:author | pubmed-author:JonkmanJ HJH | lld:pubmed |
| pubmed-article:8491237 | pubmed:author | pubmed-author:SuC ACA | lld:pubmed |
| pubmed-article:8491237 | pubmed:author | pubmed-author:SolovyJ SJS | lld:pubmed |
| pubmed-article:8491237 | pubmed:author | pubmed-author:OosterhuisBB | lld:pubmed |
| pubmed-article:8491237 | pubmed:author | pubmed-author:StormGG | lld:pubmed |
| pubmed-article:8491237 | pubmed:author | pubmed-author:CornelissenP... | lld:pubmed |
| pubmed-article:8491237 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8491237 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:8491237 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8491237 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8491237 | pubmed:pagination | 237-41 | lld:pubmed |
| pubmed-article:8491237 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:meshHeading | pubmed-meshheading:8491237-... | lld:pubmed |
| pubmed-article:8491237 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8491237 | pubmed:articleTitle | Dose-dependent uricosuric effect of ambroxol. | lld:pubmed |
| pubmed-article:8491237 | pubmed:affiliation | Pharma Bio-Research International B. V., Zuidlaren, The Netherlands. | lld:pubmed |
| pubmed-article:8491237 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8491237 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8491237 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8491237 | lld:pubmed |
